Drug products: Ebastin ABECE, Ebastin Apofri, Ebastin Ebb, Ebastin Orifarm, Kestine
ATC code: R06AX22
Controlled studies regarding sex differences in efficacy and safety of ebastine are lacking.
An analysis in healthy individuals (26 men, 63 women) receiving 20 mg ebastine showed that women excreted higher amounts of the inactive metabolite desalkylebastine than men. After adjustment of body weight, the sex difference disappeared . Another study in healthy individuals (8 men, 4 women) found no clinically relevant sex differences in pharmacokinetic parameters after treatment with 20 mg ebastine once daily for 5 days .
No studies with a clinically relevant sex analysis regarding the effects of ebastine has been found.
No studies with a clinically relevant sex analysis regarding adverse effects of ebastine has been found.
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2018-12-14
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson